CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Hippocampal-sparing Prophylactic Cranial Irradiationradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01797159
NCT01797159N/ACompleted
CompareCT.gov

"A Phase II Trial of Hippocampal-Sparing Cranial Irradiation (PCI) for Small-Cell Lung Cancer (SCLC)"

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Feb 22, 2013·Updated Oct 18, 2021

In Brief

A clinical study evaluating Hippocampal-sparing Prophylactic Cranial Irradiation for Small-cell Lung Cancer and 2 related conditions. Completed, enrolled 20 participants across 2 sites.

Detailed Summary

The Investigators are looking to compare standard treatment for the management of small cell lung cancer (SCLC) which is prophylactic cranial Irradiation (PCI) (shown to be very good in patient survival) with cranial sparing PCI. Although standard of care PCI is successful in patient survival it also has neurologic side-effects. The Investigators are hoping the cranial sparing PCI has the same positive survival results with the added benefit of lowering neurological side-effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall-cell Lung Cancer, SCLC, Small Cell Lung Cancer Limited Stage
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 22, 2013
Enrollment StartMar 11, 2013
Primary CompletionMar 18, 2018
Study CompletionMar 18, 2019
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 13.4 years ago

Interventions

Hippocampal-sparing Prophylactic Cranial Irradiationradiation

Hippocampal-sparing Prophylactic Cranial Irradiation